Luminal α-glucosidase inhibition improves insulin sensitivity and modulates glycemic and lipid profiles in obese rats with type 2 diabetes mellitus
Global Translational Medicine · 2025
DOI: 10.36922/gtm.6501 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Translational Medicine, 2025. Verfasst von Orien L. Tulp und 1 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Atherogenic plasma lipid and glycemic profiles are commonly observed in obesity and adult-onset type 2 diabetes mellitus (T2DM) and may improve following therapeutic intervention. The effects of the luminal α-glucosidase inhibitor miglitol (MIG) on carbohydrate digestion and plasma lipid profiles were evaluated in adult male obese spontaneously hypertensive and diabetes-prone/Ntul//-cp rats, a genetic model that develops early-onset obesity and T2DM independently of diet. Rats were fed either a nutritionally complete diet (formulated by the United States Department of Agriculture) containing 54% sucrose as the carbohydrate component (control) or the same diet supplemented with MIG at 150 mg/kg of diet admixture ad libitum for
Zitieren
APA
Tulp, O. L., & Rizvi, S. A. A. (2025). Luminal α-glucosidase inhibition improves insulin sensitivity and modulates glycemic and lipid profiles in obese rats with type 2 diabetes mellitus. Global Translational Medicine. https://doi.org/10.36922/gtm.6501
Vancouver
Tulp OL, Rizvi SAA. Luminal α-glucosidase inhibition improves insulin sensitivity and modulates glycemic and lipid profiles in obese rats with type 2 diabetes mellitus. Global Translational Medicine. 2025. doi:10.36922/gtm.6501
BibTeX
@article{Tulp2025,
author = {Tulp, Orien L. and Rizvi, Syed A. A.},
title = {Luminal α-glucosidase inhibition improves insulin sensitivity and modulates glycemic and lipid profiles in obese rats with type 2 diabetes mellitus},
journal = {Global Translational Medicine},
year = {2025},
doi = {10.36922/gtm.6501}
}
EUVIMED